HEAMOCOMPLETTAN P
CSL BEHRING
Identification
- Active ingredient (INN)
- FIBRINOGENE HUMAIN
- Internal code
- 12 H 223
- Country of Origin
- Germany
- Pharmaceutical form
- Powder for Injectable Sol. or Perfusion
- Prescription List
- Highly Regulated (List I)
- Packaging
- boite de 01 flacon de 1g
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Fibrinogen concentrate (human) is a hematological agent.
It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting.
It is a soluble plasma glycoprotein with a molecular weight of about 340 kDa and is a physiological substrate for three enzymes: plasmin, factor XIIIa, and thrombin.
It is indicated for the treatment of acute bleeding episodes in patients with both acquired and congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Indications
Human fibrinogen is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. 3, 6 It is also indicated for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency.
In combination with thrombin, it is used indicated as an adjunct to hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. 2,
Mechanism of Action
Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa.
The native molecule is a dimer and consists of three pairs of polypeptide chains (Aα, Bβ and γ).
Fibrinogen is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin.
During the coagulation process, thrombin cleaves the Aα and Bβ chains releasing fibrinopeptides A and B (FPA and FPB, respectively).
FPA is separated rapidly and the remaining molecule is a soluble fibrin monomer (fibrin I).
The slower removal of FPB results in formation of fibrin II that is capable of polymerization that occurs by aggregation of fibrin monomers.
The resulting fibrin is stabilized in the presence of calcium ions and by activated factor XIII, which acts as a transglutaminase.
XIIIa-induced cross-linking of fibrin polymers renders the fibrin clot more elastic and more resistant to fibrinolysis.
Cross-linked fibrin is the end result of the coagulation cascade, and provides tensile strength to a primary hemostatic platelet plug and structure to the vessel wall.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.